PT 141 Peptide (Bremelanotide): The Complete Guide to Dosage, Benefits, Side Effects & How It Works

Michael Phelps

Founder & Peptide Research Specialist, PrymaLab

Updated April 4, 2025 • 28 min read

What Is PT-141 Peptide?

PT 141 peptide, scientifically known as bremelanotide, is a synthetic cyclic heptapeptide (seven amino acids arranged in a ring structure) that belongs to the melanocortin family of peptides. Developed by Palatin Technologies and first described in the scientific literature in 2003 (Molinoff et al., Ann N Y Acad Sci, 2003), PT 141 peptide originated from research into melanocortin peptides—a class of signaling molecules derived from pro-opiomelanocortin (POMC) that regulate diverse physiological functions including skin pigmentation, appetite, energy homeostasis, and sexual behavior. The compound carries CAS registry number 189691-06-3 and PubChem CID 9941379, identifiers that distinguish it in pharmaceutical and chemical databases worldwide.

The development history of PT 141 peptide is notable for a serendipitous discovery that fundamentally redirected the compound’s clinical trajectory. The compound was originally being investigated as a synthetic tanning agent—an analog of α-MSH designed to stimulate melanin production and darken the skin without ultraviolet radiation exposure. During early clinical testing in the late 1990s and early 2000s, researchers observed unexpected and pronounced effects on sexual arousal in both male and female participants. These incidental findings, initially documented as side effects in the tanning studies, were so robust and consistent that they redirected the entire development program toward sexual dysfunction. This serendipitous pivot ultimately led to one of the most scientifically unique drug approvals in recent pharmaceutical history, transforming a failed cosmetic product into a first-in-class sexual desire medication.

On June 21, 2019, the U.S. Food and Drug Administration approved bremelanotide under the brand name Vyleesi for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. This approval was based on the two pivotal RECONNECT Phase 3 clinical trials involving 1,267 women—making PT 141 peptide only the second FDA-approved pharmaceutical for female sexual dysfunction, following flibanserin (Addyi) in 2015. Unlike flibanserin, which requires daily oral dosing, the approved formulation of PT 141 peptide is an on-demand 1.75 mg subcutaneous autoinjection pen designed for as-needed use at least 45 minutes before anticipated sexual activity, providing a fundamentally different treatment paradigm for HSDD management.

What makes PT 141 peptide fundamentally different from virtually every other sexual dysfunction treatment is its central nervous system mechanism of action. Rather than targeting the vascular system to improve blood flow (as PDE5 inhibitors like Viagra and Cialis do) or modulating serotonin receptors to gradually shift desire baseline (as flibanserin does), PT 141 peptide activates melanocortin receptors in the brain—specifically MC4R receptors in the hypothalamus and limbic system—to directly modulate the neurotransmitter pathways that regulate sexual desire and arousal. This means PT 141 peptide addresses the psychological and neurological basis of sexual dysfunction rather than just the physical mechanics, making it effective for conditions where desire itself is diminished rather than just physical response capability. For researchers interested in sexual neuroscience, PT 141 peptide represents a unique pharmacological tool for investigating the melanocortin system’s role in human sexual behavior.

PT 141 Peptide: Chemical Structure and Properties

Understanding the chemical structure of PT 141 peptide provides important context for its receptor binding properties, stability characteristics, and pharmacokinetic behavior. Bremelanotide is a cyclic lactam heptapeptide, meaning it consists of seven amino acid residues connected in a ring configuration through a lactam (amide) bond between the side chains of two residues. This cyclization is critical to the compound’s biological activity because it constrains the peptide’s three-dimensional conformation, locking it into a shape that mimics the bioactive conformation of naturally occurring α-MSH and enhancing its binding affinity for melanocortin receptors.

The amino acid sequence of PT 141 peptide is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, where Ac denotes an acetyl cap on the N-terminus, Nle is norleucine (a non-natural amino acid substitute for methionine that improves oxidative stability), and D-Phe is the D-stereoisomer of phenylalanine (which enhances metabolic resistance to enzymatic degradation). The cyclization occurs between the aspartate (Asp) and lysine (Lys) side chains, forming a 23-membered ring that restricts rotational freedom and dramatically increases binding selectivity compared to the linear parent peptide α-MSH. The molecular formula is C50H68N14O10, with a molecular weight of approximately 1,025 Da for the free base form (the acetate salt form used in research preparations has a slightly higher apparent molecular weight due to the acetate counterion).

Structural Comparison with Related Melanocortins

PT 141 peptide is structurally derived from Melanotan II (MT-II), another synthetic melanocortin analog that was developed as a tanning agent. The key structural difference is that PT 141 peptide lacks the N-terminal acetyl-norleucine residue’s amide extension that is present in MT-II, resulting in a compound that is metabolically distinct despite sharing the same core cyclic pharmacophore. Both compounds activate melanocortin receptors, but PT 141 peptide was selected for clinical development based on its more favorable pharmacokinetic profile and its ability to be formulated for on-demand subcutaneous administration. The structural relationship between α-MSH, Melanotan II, and PT 141 peptide represents a progressive refinement of melanocortin pharmacology from a linear endogenous peptide to increasingly optimized synthetic analogs with enhanced receptor selectivity and metabolic stability.

The lyophilized powder form of research-grade bremelanotide is white to off-white in appearance and is freely soluble in water and bacteriostatic water, making reconstitution straightforward. The cyclic structure confers greater enzymatic stability compared to linear peptides, contributing to its 100% subcutaneous bioavailability and its 2.7-hour plasma half-life—characteristics that make it suitable for on-demand clinical use rather than requiring the continuous infusion or frequent dosing that many linear peptides demand.

How Does PT-141 Work? The Melanocortin Receptor Mechanism

Understanding how PT 141 peptide works requires understanding the melanocortin system—a network of receptors and peptides that evolved to regulate some of the body’s most fundamental drives, including appetite, energy balance, inflammation, and sexual behavior. There are five melanocortin receptor subtypes (MC1R through MC5R), each with distinct tissue distribution and functions. Bremelanotide activates multiple melanocortin receptors with the following order of potency: MC1R > MC4R > MC3R > MC5R > MC2R (FDA Label, 2019). This multi-receptor activation profile explains both the therapeutic sexual effects (mediated primarily through MC4R) and its side effects such as nausea (potentially mediated through MC3R/MC4R in the brainstem) and skin darkening (mediated through MC1R in melanocytes).

MC4R: The Sexual Desire Receptor

The melanocortin-4 receptor (MC4R) is believed to be the primary mediator of PT 141 peptide’s sexual effects. MC4R is expressed extensively throughout the central nervous system, with particularly high concentrations in the hypothalamus, limbic system, and prefrontal cortex—brain regions that are centrally involved in processing sexual cues, desire, and reward. When bremelanotide binds to and activates MC4R, it is theorized to stimulate dopamine release in the medial preoptic area (Both, Curr Sex Health Rep, 2017), a brain region that has been directly implicated in the sexual behavior of multiple mammalian species. This dopaminergic stimulation in the medial preoptic area is thought to lower the threshold for sexual arousal, making the individual more responsive to sexual cues that might otherwise be insufficient to trigger desire in someone with HSDD.

Preclinical research by Pfaus et al. (J Sex Med, 2007) provided direct evidence for PT 141 peptide’s CNS mechanism. In female rat models, bremelanotide selectively facilitated sexual solicitation behaviors—the proactive behaviors females use to initiate sexual contact—without affecting general locomotor activity or non-sexual behaviors (Pfaus et al., PNAS, 2004). This selectivity is critical because it demonstrates that the compound specifically modulates sexual motivation pathways rather than producing a generalized CNS stimulant effect. The distinction between targeted sexual facilitation and generalized arousal is what separates bremelanotide from non-specific stimulants or mood-altering drugs that might incidentally affect sexual function as a secondary consequence of their primary pharmacological action.

MC1R: The Pigmentation Receptor

PT 141 peptide’s highest binding affinity is actually for MC1R, the melanocyte-stimulating hormone receptor found primarily in the skin. MC1R activation stimulates melanocytes to produce melanin, which is why focal hyperpigmentation (localized skin darkening) is an observed side effect. This MC1R activity is the vestige of the compound’s original development as a tanning agent and is considered an unwanted side effect in the context of sexual dysfunction treatment rather than a therapeutic benefit. The MC1R-mediated pigmentation effects tend to be localized rather than generalized and are more commonly reported with frequent long-term use over extended periods.

The Excitatory-Inhibitory Balance Model

Current neuroscience models of hypoactive sexual desire disorder propose that the condition results from an imbalance between excitatory and inhibitory neural pathways in the prefrontal cortex and limbic system. In women (and likely men) with HSDD, inhibitory signals—mediated primarily by serotonin, endogenous opioids, and endocannabinoids—dominate over excitatory ones—mediated by dopamine, norepinephrine, and melanocortins—leading to diminished responsiveness to sexual cues and reduced desire (Kingsberg et al., CNS Drugs, 2015). Melanocortins, including bremelanotide, are associated with the excitatory pathways and are linked to appetitive sexual behaviors. By activating these excitatory pathways through MC4R stimulation, PT 141 peptide is thought to restore the excitatory-inhibitory balance, enabling a normal sexual desire response rather than creating an artificial or pharmacologically forced arousal state. This model explains why the compound enhances the response to sexual cues rather than generating arousal in the absence of appropriate stimuli—an important distinction that differentiates it from aphrodisiacs or recreational drugs.

How Is PT-141 Different From Viagra and Cialis?

The distinction between PT 141 peptide and PDE5 inhibitors like Viagra (sildenafil) and Cialis (tadalafil) represents one of the most important conceptual differences in sexual dysfunction pharmacology. These drug classes target entirely different aspects of sexual function through fundamentally different mechanisms, and understanding these differences is essential for anyone researching sexual health peptides. The comparison between PT 141 peptide and PDE5 inhibitors illustrates a broader principle in sexual medicine: the difference between treating the physical mechanics of sexual response versus treating the neurological desire and arousal systems that initiate and sustain sexual motivation.

The practical implication of these differences is that PT 141 peptide and PDE5 inhibitors address fundamentally different clinical problems. A person who has normal sexual desire but difficulty achieving or maintaining an erection may benefit from a PDE5 inhibitor. A person who has diminished sexual desire or arousal—regardless of their physical capacity for sexual function—is the type of patient for whom PT 141 peptide was developed. In cases where both desire and physical function are impaired, the two mechanisms are theoretically complementary rather than mutually exclusive, although combination use has not been formally studied in clinical trials. This distinction is especially relevant for PT-141 for women, as PDE5 inhibitors have shown minimal efficacy in female sexual dysfunction due to the different pathophysiology of female sexual response.

Another important distinction concerns the drug interaction profiles. PDE5 inhibitors carry significant contraindications with nitrates and alpha-blockers due to the risk of severe hypotension. PT 141 peptide, being metabolized by peptidases rather than CYP450 enzymes, has a minimal drug-drug interaction profile. A Phase I study by Clayton et al. (Clin Ther, 2017) specifically demonstrated no significant interaction between bremelanotide and alcohol, further distinguishing the safety profile of bremelanotide from PDE5 inhibitors, which can cause enhanced hypotensive effects when combined with alcohol in some individuals.

PT-141 for Women: RECONNECT Phase 3 Clinical Trial Results

The strongest clinical evidence for PT-141 for women comes from the RECONNECT trials—two identical, Phase 3, randomized, double-blind, placebo-controlled, multicenter clinical trials that formed the basis of the FDA approval (Kingsberg et al., Obstet Gynecol, 2019). These are the most rigorous clinical studies ever conducted on PT 141 peptide and provide the definitive data on its efficacy and safety in women with hypoactive sexual desire disorder.

Study Design

The two trials (NCT02333071 and NCT02338960) enrolled a total of 1,267 premenopausal women diagnosed with acquired, generalized hypoactive sexual desire disorder according to DSM-IV-TR criteria. Participants were randomized 1:1 to receive either bremelanotide 1.75 mg or placebo, self-administered subcutaneously as needed at least 45 minutes before anticipated sexual activity. The treatment period was 24 weeks, with a maximum of 12 doses per 4-week period and no more than one dose per 24-hour period. The mean age of participants was 39 years, with 85.6% identifying as white and 96.6% enrolled at U.S. sites. The coprimary endpoints were change from baseline in the Female Sexual Function Index–Desire domain (FSFI-D) score and the Female Sexual Distress Scale–Desire/Arousal/Orgasm (FSDS-DAO) item 13 score, both assessed as the mean of monthly observations across the 24-week treatment period versus placebo.

Efficacy Results

Both RECONNECT studies successfully met their coprimary efficacy endpoints, providing robust evidence that PT-141 for women with HSDD produces meaningful improvements in both desire and distress. Women receiving bremelanotide showed statistically significant improvements in sexual desire compared to placebo, with treatment differences of +0.30 (P<.001) in Study 301, +0.42 (P<.001) in Study 302, and +0.35 (P<.001) in the integrated analysis. Distress related to low sexual desire was also significantly reduced: -0.37 (P<.001) in Study 301, -0.29 (P=.005) in Study 302, and -0.33 (P<.001) integrated. These improvements were consistent across both studies, providing the replication necessary for regulatory confidence.

The effect sizes merit context for researchers evaluating PT-141 for women. In the integrated dataset, the effect size of bremelanotide relative to placebo for improving sexual desire was 0.39, and for reducing related distress was 0.27. For comparison, the effect sizes of once-daily flibanserin (the other FDA-approved HSDD treatment) relative to placebo ranged from 0.29–0.44 for desire improvement and 0.24–0.44 for distress reduction across three Phase 3 studies. For additional perspective, SSRIs for generalized anxiety disorder have reported placebo-relative effect sizes of 0.36 (Hidalgo et al., J Psychopharmacol, 2007), and many widely prescribed psychiatric medications operate within similar effect size ranges. Treatment effects with PT 141 peptide were observed at Week 4 (the earliest evaluation point) and were sustained throughout the full 24-week treatment period, demonstrating that tolerance to the drug’s efficacy does not develop with continued use.

Long-Term Extension Data

Among the 856 patients who completed the double-blind core study, approximately 80% (684 patients) elected to participate in the open-label extension, including 87% of former placebo patients and 70% of former bremelanotide patients (Simon et al., Obstet Gynecol, 2019). The high voluntary enrollment rate among former placebo patients is particularly noteworthy because it suggests that patients who observed the benefits of PT 141 peptide in the blinded portion of the trial actively sought access to the active treatment. Long-term safety data from the extension showed no new safety signals, and the authors noted that efficacy improvements in sexual desire and distress were maintained during extended use of PT 141 peptide. One case of acute hepatitis was reported after approximately one year of use, which resolved completely after discontinuation; however, a causal relationship could not be definitively established, and no other hepatic events were observed across the program.

PT-141 for Men: What the Research Shows

While PT 141 peptide is FDA-approved exclusively for premenopausal women with HSDD, the compound has been studied in men, and the male clinical data represents an important part of the PT 141 peptide research profile. The interest in PT-141 for men is driven by the compound’s unique central mechanism of action, which addresses sexual desire at the neurological level rather than simply improving peripheral blood flow. It is essential to emphasize that PT-141 is not FDA-approved for men or for the treatment of erectile dysfunction, and any male use of the compound constitutes off-label application without the support of completed Phase 3 clinical trials. The concept of bremelanotide for men remains in the investigational category.

Diamond et al. Phase I Trial (2004)

The most frequently cited study on PT-141 for men is the Phase I randomized, double-blind, placebo-controlled trial by Diamond et al. published in the International Journal of Impotence Research (2004). This study evaluated intranasal PT-141 in two populations: healthy male subjects without visual sexual stimulation (to assess pharmacodynamic effects in the absence of erotic cues) and Viagra-responsive erectile dysfunction patients with visual sexual stimulation (to assess erectile response in a clinically relevant context). The key findings for researchers interested in PT-141 for men included statistically significant erectile responses at doses greater than 7 mg intranasally, with onset of erection occurring within approximately 30 minutes of nasal spray administration. The pharmacokinetics via the intranasal route showed a median Tmax of 0.50 hours (faster than the 1.0-hour Tmax of subcutaneous injection) and a half-life of 1.85–2.09 hours. No maximum tolerated dose was identified within the dose range studied, and the most common adverse events were flushing and nausea. The authors concluded that PT 141 peptide was “a promising candidate for further evaluation as a treatment for male ED,” suggesting significant potential for bremelanotide for men in the erectile dysfunction space.

Why PT-141 Was Not Approved for Men

Despite the promising Phase I data for PT-141 for men, the development program ultimately focused on female HSDD rather than male erectile dysfunction. Several strategic and scientific factors contributed to this decision. The male ED market was already dominated by highly effective, orally administered PDE5 inhibitors (Viagra, Cialis, Levitra) that had established safety profiles, widespread patient acceptance, and the convenience of oral dosing. PT 141 peptide’s injection-based administration was considered a significant competitive disadvantage in the male market, where oral tablets were the established standard of care and patients were unlikely to switch to an injectable product unless it offered dramatically superior efficacy. Additionally, the unmet medical need was perceived as substantially greater in female sexual dysfunction, where no on-demand treatment options existed prior to the approval of Vyleesi. The intranasal formulation of PT 141 peptide that was initially planned for male use was ultimately abandoned in favor of the subcutaneous injection that proved more reliable and consistent in pharmacokinetic studies.

Future Prospects for Bremelanotide for Men

The question of whether PT 141 peptide will eventually be formally developed for male sexual dysfunction remains open. The compound’s mechanism of action—enhancing desire through CNS melanocortin pathways—addresses a clinical need that PDE5 inhibitors cannot meet: the treatment of male hypoactive sexual desire disorder and situations where erectile dysfunction coexists with diminished libido. Some clinicians have noted that PT-141 for men could fill a gap in the therapeutic landscape by treating desire-based male sexual dysfunction, which has no FDA-approved treatments. However, the cost and complexity of conducting Phase 3 clinical trials for a second indication would be substantial, and no such trials are currently registered or publicly planned by Palatin Technologies or its licensees.

PT 141 Benefits: Complete Research Overview

The PT 141 benefits documented in clinical and preclinical research span several categories. It is important to distinguish between FDA-approved benefits (supported by Phase 3 clinical trials) and research-stage benefits (supported by earlier-phase or preclinical data only). The following overview categorizes PT 141 benefits by evidence level to provide a clear picture of what has been demonstrated versus what remains under investigation.

FDA-Approved Benefit: Increased Sexual Desire in Women with HSDD

The only FDA-approved benefit of PT 141 peptide (bremelanotide) is the treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women. Among the primary PT 141 benefits confirmed by Phase 3 data, the RECONNECT trials demonstrated statistically significant improvements in sexual desire (FSFI-D: +0.35 vs placebo, P<.001), significant reductions in sexual distress (FSDS-DAO: -0.33 vs placebo, P<.001), a 2.5-fold increase in the percentage of satisfying sexual encounters (25.0% vs 9.8%, P<.001, post hoc), and a 58% responder rate compared to 36% with placebo on the Global Assessment Questionnaire. These benefits were observed within 4 weeks of initiating treatment and were sustained over the full 24-week study period without evidence of tachyphylaxis (tolerance).

Research-Stage Benefit: Erectogenic Effects in Men

Among the research-stage PT 141 benefits, Phase I data demonstrated statistically significant erectile responses in healthy men and ED patients at intranasal doses >7 mg, with onset of erection occurring within approximately 30 minutes. This rapid erectogenic effect, combined with the compound’s unique ability to simultaneously enhance desire through central mechanisms, suggests a dual mechanism that could theoretically complement (though not replace) existing ED treatments. This remains an early-stage finding without Phase 3 confirmation, and formal clinical development of PT-141 for men with ED has not been pursued.

Research-Stage Benefit: Central Arousal Enhancement

One of the most distinctive PT 141 benefits is its central mechanism of action, which enhances both desire and arousal at the neurological level rather than operating through peripheral vascular mechanisms. Preclinical studies showed selective facilitation of sexual solicitation behaviors in female rats without affecting general activity (Pfaus et al., PNAS, 2004), indicating specific modulation of sexual motivation pathways rather than generalized stimulation. This central arousal enhancement mechanism is unique among sexual dysfunction treatments and may be particularly beneficial for individuals whose dysfunction is primarily psychological or desire-based rather than physiological in origin.

Research-Stage Benefit: Dual-Gender Applicability

PT 141 peptide is one of very few sexual function compounds with clinical evidence supporting efficacy in both men and women. While PDE5 inhibitors are exclusively male treatments and flibanserin is exclusively a female treatment, PT 141 peptide’s mechanism of activating melanocortin receptors in the brain is not sex-specific. The clinical data, while at different stages for each gender, supports meaningful effects in both sexes—making PT 141 peptide a unique compound in the sexual dysfunction research landscape and a valuable tool for studying the neuroscience of sexual desire across biological sexes.

Research-Stage Benefit: Minimal Drug Interactions

The pharmacokinetic profile of PT 141 peptide confers a notable advantage in terms of drug interaction potential. Because bremelanotide is metabolized by amide bond hydrolysis via cellular peptidases rather than by cytochrome P450 enzymes, PT 141 peptide has minimal potential for pharmacokinetic drug-drug interactions. This was confirmed by the alcohol interaction study (Clayton et al., Clin Ther, 2017) and the overall clinical program, which identified no clinically significant interactions. For patients taking multiple medications—a common scenario in the target HSDD population—this minimal interaction profile represents an important practical advantage among PT 141 benefits.

PT 141 Dosage: FDA-Approved and Research Protocols

PT 141 dosage varies depending on whether one is discussing the FDA-approved pharmaceutical product (Vyleesi) or the research-grade peptide. Understanding the distinction between these two contexts is essential for anyone researching PT 141 peptide, as they involve different formulations, concentrations, and dosing paradigms. The correct PT 141 dosage depends on the route of administration, the individual’s tolerance profile, and whether the use case is the FDA-approved indication or an off-label research application.

FDA-Approved Dosage (Vyleesi)

The FDA-approved PT 141 dosage regimen for Vyleesi is precisely defined based on extensive dose-finding studies: 1.75 mg administered subcutaneously via an autoinjection pen at least 45 minutes before anticipated sexual activity. The labeling specifies that patients should not use more than one dose within a 24-hour period and should not exceed approximately 12 doses per month (roughly one every other day). This PT 141 dosage was selected based on Phase 2b dose-finding data (Clayton et al., Womens Health, 2016), which evaluated doses of 0.75 mg, 1.25 mg, and 1.75 mg in a randomized trial of 327 premenopausal women with HSDD. The 1.75 mg dose demonstrated optimal efficacy with an acceptable safety profile and was chosen for the pivotal Phase 3 RECONNECT trials. The 0.75 mg dose did not separate from placebo on the primary endpoint, while the 1.25 mg dose showed intermediate effects, supporting a dose-response relationship.

Research Community Protocols

In the research peptide community, off-label PT 141 dosage protocols for both men and women commonly reference a broader dose range than the FDA-approved 1.75 mg. Common protocols include starting doses of 0.5–1.0 mg subcutaneously to assess individual tolerance (particularly nausea sensitivity), with titration upward to 1.5–2.0 mg based on response and tolerability. The rationale for starting at a lower PT 141 dosage than the FDA-approved dose is that nausea incidence appears to be dose-dependent, and some individuals report effective responses at doses below 1.75 mg. Male protocols often reference slightly higher doses (1.0–2.0 mg subcutaneously), extrapolated from the Phase I intranasal data where doses above 7 mg intranasally (which has substantially lower bioavailability than subcutaneous injection) produced significant erectile responses.

PT-141 Dosage for Women vs Men

There is no established evidence that the optimal PT 141 dosage differs between men and women when administered subcutaneously. The FDA-approved 1.75 mg dose was established in the female HSDD population, and no corresponding dose-finding studies have been published for male subcutaneous use. The Phase I male study used intranasal doses of 7–20 mg, but intranasal bioavailability is substantially lower than subcutaneous, so these doses are not directly comparable. Community protocols for PT-141 for men generally reference similar subcutaneous doses (1.0–2.0 mg) to those used in women, though some male users report effective responses at higher doses within this range. The PT-141 dosage for women should follow the FDA-approved protocol when possible, starting at 1.75 mg as the evidence-based dose.

PT-141 Dosage Calculator: Reconstitution Guide

Research-grade PT 141 peptide is typically supplied as a lyophilized (freeze-dried) powder in vials containing either 5 mg or 10 mg of peptide. This PT-141 dosage calculator section provides the reconstitution mathematics needed to prepare accurate doses from these standard vial sizes. Reconstitution with bacteriostatic water (BAC water) is required before administration. The amount of water added determines the concentration of the resulting solution, which in turn determines the volume of solution needed per dose. The following reconstitution tables provide reference calculations for common vial sizes and dose targets used in PT 141 peptide research.

5 mg Vial Reconstitution

10 mg Vial Reconstitution

How to Use the PT-141 Dosage Calculator

To calculate any PT 141 dosage volume from a reconstituted vial, use this formula: Volume (mL) = Desired Dose (mg) ÷ Concentration (mg/mL). On a standard U-100 insulin syringe, each “unit” mark corresponds to 0.01 mL, so multiply your calculated volume by 100 to determine the number of units to draw. For example, if you reconstituted a 10 mg vial with 2.0 mL of bacteriostatic water (creating a 5.0 mg/mL concentration) and want a 1.75 mg dose: 1.75 ÷ 5.0 = 0.35 mL = 35 units on an insulin syringe.

When reconstituting PT 141 peptide, always inject the bacteriostatic water slowly down the inner wall of the vial and swirl gently to dissolve—never shake the vial vigorously, as this can denature the peptide through mechanical stress and reduce potency. The solution should appear clear and colorless after reconstitution; discard any vial that shows particulate matter, cloudiness, or discoloration. Store reconstituted PT 141 peptide at 2–8°C (refrigerator) and use within 4–6 weeks for optimal potency, as peptides gradually degrade even under refrigeration once in solution.

PT-141 Nasal Spray: Is It Effective?

The PT-141 nasal spray formulation has a significant history in the compound’s development and remains a topic of considerable interest in the research community. The earliest clinical trials of PT 141 peptide—including the Diamond et al. Phase I trial in men—used an intranasal delivery route, and the initial development plan envisioned a PT-141 nasal spray as the primary commercial formulation for both men and women. Understanding the history, evidence, and limitations of the PT-141 nasal spray is important for researchers comparing delivery routes for PT 141 peptide.

Clinical Evidence for Intranasal PT-141

In the Diamond et al. (2004) study, the PT-141 nasal spray demonstrated dose-dependent absorption with a median Tmax of 0.50 hours (faster than the 1.0-hour Tmax of subcutaneous injection) and a half-life of 1.85–2.09 hours. Erectile responses were statistically significant at doses greater than 7 mg intranasally, and the onset of the first erection occurred within approximately 30 minutes. However, it is important to note that intranasal bioavailability is substantially lower than subcutaneous bioavailability (which is 100%), meaning significantly higher doses of PT 141 peptide are required intranasally to achieve comparable systemic exposure. This pharmacokinetic reality explains the large difference between the effective intranasal dose (>7 mg) and the effective subcutaneous dose (1.75 mg) for PT 141 peptide.

Why the PT-141 Nasal Spray Was Abandoned for FDA Approval

Despite the convenience of nasal delivery, the development program ultimately shifted from the PT-141 nasal spray to subcutaneous injection for several compelling reasons. First, intranasal absorption of PT 141 peptide was more variable between individuals and between administrations in the same individual, leading to less predictable pharmacokinetics and inconsistent dose-response relationships. Second, the higher intranasal doses required to compensate for lower bioavailability were associated with greater blood pressure effects than the lower subcutaneous doses, raising cardiovascular safety concerns at the doses needed for efficacy. Third, the subcutaneous autoinjection pen provided the most consistent pharmacokinetic profile for regulatory approval purposes, which was critical for demonstrating reliable efficacy in the Phase 3 trials.

Current Research PT-141 Nasal Spray Products

Some research peptide suppliers offer PT 141 peptide in pre-formulated PT-141 nasal spray devices, typically containing a set concentration of reconstituted bremelanotide delivered in metered-dose actuations. These products are not FDA-approved and are sold for research purposes only. Researchers should be aware that PT-141 nasal spray requires significantly higher doses than subcutaneous PT 141 peptide to achieve comparable systemic exposure, and the absorption can be affected by factors such as nasal congestion, mucosal condition, recent use of other nasal products, and spray technique. For those seeking the most predictable and research-validated dosing of PT 141 peptide, subcutaneous injection remains the gold standard based on its 100% bioavailability and consistent pharmacokinetic profile.

What Are the Side Effects of PT-141?

PT 141 peptide has one of the most thoroughly characterized side effect profiles of any research peptide, thanks to the extensive Phase 2 and Phase 3 clinical trial data generated during its FDA approval process. Understanding the PT 141 side effects is essential for risk assessment, and the RECONNECT trials enrolled 1,247 women in the safety population, providing robust data on adverse event incidence, severity, onset, duration, and management strategies.

Common Side Effects (RECONNECT Trial Data)

Managing Nausea: The Primary Tolerability Challenge

Nausea is by far the most significant tolerability issue among PT 141 side effects, affecting 40% of women in the clinical trials. However, several important contextual factors moderate this finding and provide strategies for management. First, the nausea was mild to moderate in approximately 98% of cases and resolved spontaneously without medical intervention. The median onset was approximately 30 minutes after dosing of PT 141 peptide, with a median duration of 2.4 hours. Second, only 8.1% of patients discontinued treatment due to nausea, meaning that the vast majority of affected patients found the nausea manageable enough to continue treatment and experience the sexual desire benefits. Third, nausea tended to occur sporadically rather than with every dose, and antiemetic use reduced subsequent nausea rates to approximately 5% (compared to approximately 15% without antiemetics). Fourth, anecdotal reports from the research community suggest that starting at a lower PT 141 dosage (0.5–1.0 mg rather than the full 1.75 mg) and titrating upward may significantly reduce initial nausea incidence while still providing meaningful effects on desire.

Blood Pressure Effects

PT 141 peptide produces small, transient increases in blood pressure: approximately 3 mmHg systolic and 2 mmHg diastolic, peaking within 2–4 hours of dosing and returning to baseline within 8–10 hours. These changes were accompanied by corresponding reductions in heart rate, resulting in no net increase in overall myocardial workload. The intermittent, as-needed dosing pattern of PT 141 peptide means these transient BP changes do not produce cumulative or sustained effects on cardiovascular health. Nevertheless, patients with uncontrolled hypertension or cardiovascular disease should exercise caution, and the Vyleesi prescribing information recommends monitoring blood pressure in patients with a history of cardiovascular disease.

Hyperpigmentation

Focal hyperpigmentation (localized skin darkening) has been reported uncommonly among PT 141 side effects. This effect results from MC1R activation stimulating melanocyte activity and melanin production—the same mechanism that originally made PT 141 peptide of interest as a tanning agent. While generally cosmetic and harmless, darkening around the face, gums, breasts, or injection site has been reported in some long-term users. This side effect may be more pronounced in individuals with darker skin tones and those who use the compound frequently over extended periods. In clinical trials, hyperpigmentation was reported at low incidence and did not lead to treatment discontinuation.

Contraindications

The FDA labeling for Vyleesi identifies specific contraindications for PT 141 peptide use. The compound is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease due to the transient blood pressure effects. It is also not recommended for use during pregnancy or breastfeeding, as reproductive toxicology data is limited. Bremelanotide should not be used concurrently with naltrexone or other melanocortin receptor antagonists that could attenuate its effects. Importantly, no clinically significant laboratory, ECG, weight, depression, or suicidal ideation effects were observed across the clinical trial program, and no deaths occurred in either RECONNECT study.

PT-141 Pharmacokinetics and Duration of Action

The pharmacokinetic profile of PT 141 peptide has been thoroughly characterized in multiple clinical studies across both subcutaneous and intranasal routes of administration. Understanding these parameters helps researchers and clinicians predict onset, peak effect, duration of action, and appropriate dosing intervals for PT 141 peptide.

The practical interpretation of these pharmacokinetics is that PT 141 peptide reaches peak effect within about an hour after subcutaneous injection, with 100% of the administered dose reaching systemic circulation. The 2.7-hour half-life means that plasma concentrations decline by approximately 50% every 2.7 hours, so significant pharmacological activity can be expected for roughly 4–6 hours after dosing, with diminishing effects thereafter. After approximately 5 half-lives (roughly 13.5 hours), the compound is essentially cleared from the body, which is consistent with the recommended 24-hour minimum between doses.

The minimal drug-drug interaction profile (due to peptidase metabolism rather than CYP450 metabolism) is a notable clinical advantage. Unlike many small-molecule drugs that are processed by liver enzymes and can interact with a wide range of other medications through enzyme inhibition or induction, bremelanotide is broken down by ubiquitous peptidases through simple amide bond hydrolysis. This means the compound is unlikely to interact with other medications the patient may be taking, including oral contraceptives, antidepressants, antihypertensives, and other commonly prescribed drugs in the target population.

Is PT-141 Legal? FDA Status and Regulatory Considerations

The legal status of PT 141 peptide has two distinct dimensions: the pharmaceutical product and the research peptide, each governed by different regulatory frameworks. Understanding these distinctions is essential for researchers, clinicians, and individuals interested in PT 141 peptide.

Vyleesi (Pharmaceutical Product)

Bremelanotide under the brand name Vyleesi is a prescription pharmaceutical approved by the FDA since June 21, 2019. It is legally available in the United States with a valid prescription for the treatment of acquired, generalized HSDD in premenopausal women. Vyleesi is classified as a prescription drug (not a controlled substance), meaning it does not carry DEA scheduling and is not subject to the prescribing restrictions that apply to controlled substances. Prescribing PT 141 peptide (as Vyleesi) for off-label uses—including for male patients or postmenopausal women—is at the physician’s discretion, as off-label prescribing is legal in the United States when the physician determines it is medically appropriate based on the available evidence.

Research-Grade PT 141 Peptide

Research-grade bremelanotide is sold by research chemical suppliers under the designation “for research purposes only” and “not for human consumption.” This product exists in a legal gray area: it is legal to purchase and possess for legitimate research purposes in most jurisdictions, but it is not FDA-approved for self-administration. The distinction between the pharmaceutical Vyleesi product (manufactured under cGMP conditions with strict quality controls) and research-grade peptide (variable quality depending on supplier) is significant from both a safety and regulatory perspective. The research-grade product undergoes different manufacturing and quality control processes than pharmaceutical-grade bremelanotide, and the two should not be considered interchangeable.

International Considerations

Bremelanotide is not classified as a controlled substance in most jurisdictions worldwide. It is not on the WADA Prohibited List for competitive athletes, though athletes should always verify their sport’s specific regulations. However, regulatory status varies by country, and individuals should verify their local regulations regarding peptide research chemicals. In some countries, PT 141 peptide may be available through compounding pharmacies with a prescription, while in others it may be restricted or entirely unavailable. The European Medicines Agency has not approved bremelanotide, so pharmaceutical-grade Vyleesi is generally unavailable in European markets, though research-grade bremelanotide may be accessible through international research chemical suppliers.

PT 141 Peptide Storage and Handling

Proper storage and handling of PT 141 peptide is critical for maintaining the compound’s potency and ensuring accurate dosing throughout the life of each vial. As a peptide, bremelanotide is susceptible to degradation through hydrolysis, oxidation, and thermal denaturation, and the storage conditions significantly impact how long PT 141 peptide remains active and stable.

Lyophilized (Unreconstituted) PT 141 Peptide

In its lyophilized powder form, PT 141 peptide is relatively stable. Store unreconstituted vials at -20°C (freezer) for long-term storage (up to 24 months or beyond), or at 2–8°C (refrigerator) for medium-term storage (6–12 months). At room temperature (15–25°C), lyophilized bremelanotide remains stable for shorter periods (weeks to a few months), making brief exposure during shipping generally acceptable. Keep vials away from direct light and moisture, and ensure the rubber stopper seal remains intact to prevent humidity exposure. The lyophilized form is the most stable state for the compound and should be maintained until reconstitution is needed.

Reconstituted PT 141 Peptide

Once reconstituted with bacteriostatic water, the peptide begins to degrade more rapidly due to the aqueous environment facilitating hydrolysis of the amide bonds. Store reconstituted PT 141 peptide at 2–8°C (refrigerator) and use within 4–6 weeks for optimal potency. Do not freeze reconstituted peptide, as ice crystal formation can damage the peptide structure. If using sterile water (without the bacteriostatic preservative benzyl alcohol), use the reconstituted solution within 48–72 hours to minimize the risk of microbial contamination, as sterile water provides no ongoing preservative effect. Always use aseptic technique when drawing from a multi-use vial—swab the rubber stopper with alcohol before each withdrawal.

Signs of Degradation

Properly prepared The reconstituted solution should be clear, colorless, and free of particulate matter. Discard any reconstituted vial that shows cloudiness, particulate matter, color change (yellowing or browning), or an unusual odor. These changes may indicate peptide aggregation, oxidation, microbial contamination, or thermal denaturation. If the solution develops any of these characteristics, its potency and safety cannot be assured, and a fresh vial should be reconstituted.

Buying PT 141 Peptide for Research: Quality and Safety

When purchasing research-grade PT 141 peptide, quality verification is essential because the compound is a synthetic peptide that can degrade, be contaminated, or be under-dosed if not manufactured and handled properly. The difference between high-quality and low-quality PT 141 peptide can be the difference between reliable research results and wasted time and resources.

Certificate of Analysis (CoA)

Every reputable supplier should provide a batch-specific Certificate of Analysis from an independent, accredited laboratory. The CoA should include HPLC purity analysis (target: ≥98% purity for research-grade bremelanotide), mass spectrometry confirmation of molecular identity (expected molecular weight for bremelanotide: ~1,025 Da for the free base), endotoxin testing results (LAL assay; important for injectable peptides), and appearance/solubility data. Request the CoA before purchasing and verify that it corresponds to the specific batch you will receive rather than a generic or representative analysis from a different lot.

Supplier Selection Criteria

Reliable suppliers demonstrate transparency about their manufacturing processes and peptide synthesis methods, provide responsive and knowledgeable customer service, maintain consistent product quality across batches (verifiable through multiple CoAs), and clearly label their products with appropriate research-use disclaimers. Look for suppliers with established reputations in the research community, verified third-party testing from recognized analytical laboratories, proper cold-chain shipping practices (ice packs, insulated packaging, or dry ice for temperature-sensitive shipments), and clear product labeling that includes peptide content, lot number, manufacturing date, and expiration date. Avoid suppliers that make medical claims, suggest specific therapeutic uses, guarantee specific results, or refuse to provide documentation when requested.

Red Flags to Avoid

Several warning signs indicate a potentially unreliable supplier: prices that are dramatically below market average (suggesting under-dosing or contamination), no Certificate of Analysis available or only a generic CoA not tied to a specific batch, medical claims or therapeutic use suggestions on the website, no verifiable business address or contact information, packaging that lacks lot numbers or expiration dates, and no cold-chain shipping options for temperature-sensitive peptide products. Research-grade bremelanotide from reputable manufacturers typically costs within a consistent market range, and prices that seem too good to be true usually are.

Frequently Asked Questions About PT 141 Peptide